Earnings Alphatec Holdings reported consolidated revenues for 1Q:08 of $23.2 million, an increase of 19% from the year-ago period. U.S. revenues for the first quarter of 2008 were $18.6 million, an increase of 12% from the year-ago period. Asia revenues... more
M&A Kinetic Concepts, Inc. announced plans to acquire LifeCell for $1.7 billion, or $51.00 per share, which represents an 18% premium over LifeCell's closing price on Friday and a 26% premium over the 90-day volume weighted average trading price. KCI... more
Kinetic Concepts, Inc. announced this morning its plans to acquire LifeCell for $1.7 billion, or $51.00 per share, which represents an 18% premium over LifeCell's closing price on Friday and a 26% premium over the 90-day volume weighted average trading... more
Earnings aap Implantate reported 2007 revenue of EUR 28.0 million ($41.24 million), an increase of 52% over 2006. Net profit for the year was EUR 1.5 million ($2.21 million), down from EUR 1.6 million ($2.36 million) in 2006, which the... more
Earnings Artimplant reported 4Q:07 revenues of SEK 5.0 million ($0.8 million), up from SEK 1.6 million ($0.25 million) in the year-ago period. The net loss for 4Q:07 was SEK 2.1 million ($0.34 million), improved from a loss of SEK 9.5... more
Earnings ArthroCare Corp. reported 3Q:07 total revenues of $78.5 million, an increase of 21% over the comparable quarter. Revenues missed estimates by $0.11 million. The company reported net income of $11.1 million, or $0.39 per share, up 28% over 3Q:06... more
Earnings Stryker reported revenues of $1.46 billion, beating estimates of $1.44 billion and increasing 16% from $1.26 billion in 2Q:06. 2Q:07 earnings were $269.1 million, or $0.65 per share, beating estimates of $0.61 and up from $0.52 in the comparable... more
Earnings Large Joints Zimmer reported income of $233.4 million, or $0.98 per share, beating estimates of $0.93. The quarter compares to a profit of $205.6 million, or $0.82 per share in 1Q:06. Revenue rose 10% to $950.2 million from $860.4... more
Earnings Biologics LifeCell reported 4Q:06 product revenues of $39.3 million, an increase of 45% over $27.0 million in 4Q:05, but missed analysts' estimates of $39.5 million. The growth was attributed to increased demand for the Company's AlloDerm® Regenerative Tissue Matrix.... more
February 2010 update: This report is no longer available for purchase. Learn more here. Even though processor scandals have tainted the allograft business, human bone graft isn't going away anytime soon. It's too important to spinal fusion and many other... more
February 2010 update: This report is no longer available for purchase. Learn more here. This is a sample chapter from our new research report on Allograft. Learn more about the report here, and purchase and download it for $279 from... more
LifeCell Corporation, a maker of regenerative human tissue products, yesterday reported record 2Q:06 financial results. Product revenues were $35.7 million for the quarter, up 60% from the $22.3 million reported in 2Q:05. Growth in product revenues can be attributed to... more
Earnings Results: Biologics: Anika Therapeutics announced 2Q:06 net sales increased 11% to $7.1 million. Product revenues grew 74% while licensing, milestone and contract revenue was down 77%. The large product sales growth was partially driven by higher demand for OrthoVisc®;... more
The first group of orthopedic companies reported their 1Q:06 this week and took in $5.3 billion so far. The total aggregated revenues for the quarter were up by 7% from $4.9 billion in 1Q:05. The industry netted $637.8 million, a... more
In the swarm of public earnings reports for the first quarter, we thought LifeCell's results were particularly newsworthy. Thanks to the Company's AlloDerm Regenerative Tissue Matrix which grew at an astounding 69% year-over-year ($25.3 million in 1Q:06 compared to $14.9... more
Many orthopedic companies will be reporting their 1Q:06 results in the next few weeks. The table below provides a listing of conference call dial-in numbers and webcasts for the investment community. How the overall orthopedic industry fared in the first... more
This week at HealthpointCapital, we compiled a brief synopsis of the 2006 Orthopedic Industry, projecting that total revenue in 2006 will grow by 12% for the year. Appointment: Two notable extremities companies named their new CEOs this week: Wright Medical... more
Although management teams are preparing for AAOS, a few more companies reported earnings this week. We did a quick calculation and found that our internal Orthopedic Index PE year-to-date has stayed relatively flat at 27x. We expect that the AAOS... more
In a very surprising trading session, LifeCell fell 13% on Tuesday after reporting a very positive 4Q:05. The Company reported that earnings totaled $0.11 per share which was in-line with analyst expectations and a 175% increase over the prior year.... more
LifeCell reported that it anticipates 4Q:05 product revenues of $27 million which is a 69% increase over the 4Q:04. Product revenues were driven by an 84% increase in Alloderm sales. Orthopedic Product Revenues, which consist of GraftJacket and AlloCraft DBM... more
It has been a busy week for many CEOs and CFOs in the orthopedic device sector. In the past two weeks orthopedic companies reported 3Q:05 sales of $4.7 billion which was a 12% increase over the 3Q:04. Net earnings for... more
Some orthopedic stocks declined as two of the big five ortho-companies reported their 3Q:05 earnings this week. Stryker Corp. and DePuy (division of JNJ) both reported top line sales growing at 14%. On Tuesday, Stryker reported below street's estimates by... more
The allograft industry was scrutinized recently due to the highly publicized case of Biomedical Tissue Services (BTS). The company is being investigated by the Brooklyn district attorney's office for operating a scam to profit from body parts. The first company... more
Thanks to one of our readers who reminded me that I should add international dial-in numbers to the conference calls list. Since most of the companies have already reported their earnings, I am providing you with replay information in case... more
Earnings: Please refer to the table (below) for individual company sales and earnings. It's all about earnings this week... Biologics: Clearly, the big winner this week is LifeCell Corp. who reported strong earnings on Monday stock was up 24% at... more
The NYT runs an astute roundup (registration required) of the the "depressing" delay by some insurers to cover Charite surgery. they note the market tumult that might be caused by possible FDA approval of Synthes' ProDisc, Medtronic's Maverick, and Stryker's... more
The allograft market has been extremely volatile during the last five years providing investors both short and long return opportunities. Five years ago the allograft soft tissue market was dominated by CryoLife which had a market capitalization of $300 million... more
LIFC reported strong product revenue growth in 1Q:05 as sales increased by 48%.' Product sales totaled $19.7 million compared to $13.3 million in 1Q:04. Sales were driven by higher demand for the AlloDerm® Regenerative Tissue Matrix used in complex hernia... more
LifeCell Corp. (NASDAQ:LIFC) reported a strong 49% increase in product revenues in 4Q:04 which was in line with consensus estimate of $0.04 per diluted share on a non-GAAP reporting standard. Product revenues in the 4Q:04 were $16 million compared to... more
We have aggregated the 4Q:04 and 3Q:04 reported revenues (includes the effects of foreign currency) for 16 public orthopedic companies. Although we would have liked to use revenue growth rates which excluded foreign currency, a majority of the companies report... more
LIFC reported that it anticipated 4Q:04 product revenues to total $16.0 million which is a 49% increase over the 4Q:03. The company is anticipating 2004 product revenues to total $59 million compared to the $39 million reported during 2003 (52%... more
Alloderm, LifeCell's donated decellularized human dermal tissue, just continues to gain surgeon champions at what appears to be accelerating rates. Alloderm sales reached $11 in the September quarter, up 71% from the prior year's $6.4 million in sales for the... more
Headlining this year's one-day Biomaterials Summit will be Wright Medical, Regeneration Technologies, LifeCell, Orthovita, MacroPore and Stellar International. All are leaders in the field and working on significant new technologies. Wright Medical, whose sales for the first half of 2004... more
For the June quarter, LIFC reported that sales hit $15.1 million, a stellar 58% increase over prior year levels. Sales for the superstar product, Alloderm', accounted for 68% of the overall sales and rose 89% over prior year levels. The... more
Watch what is happening in hernia repair and then start thinking cartilage, tendon and ligament. LifeCell, which could call itself a 'biomaterial' company, but won't - posted the #1 rate of revenue growth of all 'biomaterials' companies with an impressive... more
Stryker Corp. (SYK:NYSE), in similar fashion to last year, brought and introduced a majority of its operational leaders of its various operating divisions. However, a significant portion of the analyst meeting, especially Q&A, centered around Stephen MacMillan, President & COO,... more
LifeCell continues to post very impressive top line growth. Sales in the fourth quarter broke out of its sub-$10 million plateau and reached a solid $11.1 million. For the past six quarters LifeCell has been posting between $8-10 million in... more
Capital markets aren't rational. Otherwise, they'd have longer memories. A year ago, when Zimmer was trading at $40.01, DJ Orthopedics was at $3.66, Encore was at $3.20 and LifeCell was at $2.89, you couldn't buy an orthopedic or medical device... more
Complete Archive
